376 related articles for article (PubMed ID: 16210663)
1. Inhibition of NK cell activity through TGF-beta 1 by down-regulation of NKG2D in a murine model of head and neck cancer.
Dasgupta S; Bhattacharya-Chatterjee M; O'Malley BW; Chatterjee SK
J Immunol; 2005 Oct; 175(8):5541-50. PubMed ID: 16210663
[TBL] [Abstract][Full Text] [Related]
2. [Effects of NKG2D and its ligands RAE-1 and H60 on graft-versus-tumor response].
Li XF; Chen Q; Ye YB; Fan LF; Chen MS; Li JY; Chen HQ; Chen SP; Zhou ZF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Feb; 15(1):160-4. PubMed ID: 17490545
[TBL] [Abstract][Full Text] [Related]
3. Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients.
Lee JC; Lee KM; Kim DW; Heo DS
J Immunol; 2004 Jun; 172(12):7335-40. PubMed ID: 15187109
[TBL] [Abstract][Full Text] [Related]
4. Recombinant vaccinia virus expressing interleukin-2 invokes anti-tumor cellular immunity in an orthotopic murine model of head and neck squamous cell carcinoma.
Dasgupta S; Bhattacharya-Chatterjee M; O'Malley BW; Chatterjee SK
Mol Ther; 2006 Jan; 13(1):183-93. PubMed ID: 16125469
[TBL] [Abstract][Full Text] [Related]
5. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma.
Doubrovina ES; Doubrovin MM; Vider E; Sisson RB; O'Reilly RJ; Dupont B; Vyas YM
J Immunol; 2003 Dec; 171(12):6891-9. PubMed ID: 14662896
[TBL] [Abstract][Full Text] [Related]
6. IFN-dependent down-regulation of the NKG2D ligand H60 on tumors.
Bui JD; Carayannopoulos LN; Lanier LL; Yokoyama WM; Schreiber RD
J Immunol; 2006 Jan; 176(2):905-13. PubMed ID: 16393975
[TBL] [Abstract][Full Text] [Related]
7. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity.
Diefenbach A; Jensen ER; Jamieson AM; Raulet DH
Nature; 2001 Sep; 413(6852):165-71. PubMed ID: 11557981
[TBL] [Abstract][Full Text] [Related]
8. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages.
Diefenbach A; Jamieson AM; Liu SD; Shastri N; Raulet DH
Nat Immunol; 2000 Aug; 1(2):119-26. PubMed ID: 11248803
[TBL] [Abstract][Full Text] [Related]
9. A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity.
Diefenbach A; Hsia JK; Hsiung MY; Raulet DH
Eur J Immunol; 2003 Feb; 33(2):381-91. PubMed ID: 12645935
[TBL] [Abstract][Full Text] [Related]
10. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice.
Cerwenka A; Bakker AB; McClanahan T; Wagner J; Wu J; Phillips JH; Lanier LL
Immunity; 2000 Jun; 12(6):721-7. PubMed ID: 10894171
[TBL] [Abstract][Full Text] [Related]
11. Tumor metastasis in an orthotopic murine model of head and neck cancer: possible role of TGF-beta 1 secreted by the tumor cells.
Dasgupta S; Bhattacharya-Chatterjee M; O'Malley BW; Chatterjee SK
J Cell Biochem; 2006 Apr; 97(5):1036-51. PubMed ID: 16294321
[TBL] [Abstract][Full Text] [Related]
12. NKG2D receptor-mediated NK cell function is regulated by inhibitory Ly49 receptors.
Regunathan J; Chen Y; Wang D; Malarkannan S
Blood; 2005 Jan; 105(1):233-40. PubMed ID: 15328154
[TBL] [Abstract][Full Text] [Related]
13. Correlation Between NKG2DL Expression and Antitumor Effect of Protein-bound Polysaccharide-K in Tumor-bearing Mouse Models.
Konagai A; Yoshimura K; Hazama S; Yamamoto N; Aoki K; Ueno T; Fujioka M; Iijima H; Kato M; Uchida M; Wada T; Inoue M; Asao T; Fuse M; Wada S; Kuramasu A; Kamei R; Takeda S; Yamamoto S; Yoshino S; Oka M; Nagano H
Anticancer Res; 2017 Aug; 37(8):4093-4101. PubMed ID: 28739693
[TBL] [Abstract][Full Text] [Related]
14. The cytomegalovirus m155 gene product subverts natural killer cell antiviral protection by disruption of H60-NKG2D interactions.
Lodoen MB; Abenes G; Umamoto S; Houchins JP; Liu F; Lanier LL
J Exp Med; 2004 Oct; 200(8):1075-81. PubMed ID: 15477345
[TBL] [Abstract][Full Text] [Related]
15. IL-2/IL-18 prevent the down-modulation of NKG2D by TGF-beta in NK cells via the c-Jun N-terminal kinase (JNK) pathway.
Song H; Hur DY; Kim KE; Park H; Kim T; Kim CW; Bang S; Cho DH
Cell Immunol; 2006 Jul; 242(1):39-45. PubMed ID: 17070508
[TBL] [Abstract][Full Text] [Related]
16. Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells.
Castriconi R; Cantoni C; Della Chiesa M; Vitale M; Marcenaro E; Conte R; Biassoni R; Bottino C; Moretta L; Moretta A
Proc Natl Acad Sci U S A; 2003 Apr; 100(7):4120-5. PubMed ID: 12646700
[TBL] [Abstract][Full Text] [Related]
17. Interleukin 2 gene transfer prevents NKG2D suppression and enhances antitumor efficacy in combination with cisplatin for head and neck squamous cell cancer.
Li D; Ronson B; Guo M; Liu S; Bishop JS; Van Echo DA; O'Malley BW
Cancer Res; 2002 Jul; 62(14):4023-8. PubMed ID: 12124336
[TBL] [Abstract][Full Text] [Related]
18. Gene therapy for head and neck cancer using vaccinia virus expressing IL-2 in a murine model, with evidence of immune suppression.
Qin H; Valentino J; Manna S; Tripathi PK; Bhattacharya-Chatterjee M; Foon KA; O'Malley BW; Chatterjee SK
Mol Ther; 2001 Dec; 4(6):551-8. PubMed ID: 11735339
[TBL] [Abstract][Full Text] [Related]
19. Molecular competition for NKG2D: H60 and RAE1 compete unequally for NKG2D with dominance of H60.
O'Callaghan CA; Cerwenka A; Willcox BE; Lanier LL; Bjorkman PJ
Immunity; 2001 Aug; 15(2):201-11. PubMed ID: 11520456
[TBL] [Abstract][Full Text] [Related]
20. Human tumor-derived exosomes down-modulate NKG2D expression.
Clayton A; Mitchell JP; Court J; Linnane S; Mason MD; Tabi Z
J Immunol; 2008 Jun; 180(11):7249-58. PubMed ID: 18490724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
